Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1999;8(2):101–106. doi: 10.1080/09629359990595

Expression of Bcl-2 in inflammatory sites from patients with active Behçet's disease.

K Hamzaoui 1, A Hamzaoui 1, L Zakraoui 1, A Chabbou 1
PMCID: PMC1781785  PMID: 10704147

Abstract

Behçet's disease (BD) is a current systemic vasculitis of unknown aetiology. Eyes, skin, joints, the oral cavity, genital system, blood vessels, central nervous system and lung are usually involved. Defective regulation of programmed cell death (apoptosis) may play a role in the development of (BD), and the proto-oncogene Bcl-2 is involved in the control of apoptosis in immunocompetent cells. We therefore wished to investigate the expression of Bcl-2 in the peripheral lymphocytes and in two inflammatory sites of patients with active BD: bronchoalveolar lavage (BAL) and cerebrospinal fluid (CSF) lymphocytes. Levels of Bcl-2 expression in the lymphocytes of patients with BD and, for comparison, in the lymphocytes of healthy controls and non-inflammatory neurological diseases (NIND), were studied by two-colour cytofluorography and RNA analysis. In BD patients, a significant proportion of T cells expressed increased amounts of Bcl-2 protein, both in peripheral blood and in inflammatory sites. Mononuclear cells of patients with BD showed increased amount of Bcl-2 messenger RNA. The in vitro incubation of T lymphocytes with IL-10, significantly increased the Bcl-2 expression, specifically in T lymphocytes from inflammatory sites. In active BD, stimulation of HSV-1 T lymphocytes slightly increased Bcl-2 expression, not significantly different from unstimulated HSV-1 T cells. The occurrence of circulating T lymphocytes with abnormally high Bcl-2 expression in peripheral circulation and in inflammatory sites may be explained in part by the increased in vivo activation levels, and by aetiopathological agent(s): our findings seem to indicate an important role in the chronic inflammation in BD.

Full Text

The Full Text of this article is available as a PDF (164.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akbar A. N., Borthwick N., Salmon M., Gombert W., Bofill M., Shamsadeen N., Pilling D., Pett S., Grundy J. E., Janossy G. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J Exp Med. 1993 Aug 1;178(2):427–438. doi: 10.1084/jem.178.2.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aringer M., Wintersberger W., Steiner C. W., Kiener H., Presterl E., Jaeger U., Smolen J. S., Graninger W. B. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum. 1994 Oct;37(10):1423–1430. doi: 10.1002/art.1780371004. [DOI] [PubMed] [Google Scholar]
  3. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  4. Cohen S. B., Crawley J. B., Kahan M. C., Feldmann M., Foxwell B. M. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology. 1997 Sep;92(1):1–5. doi: 10.1046/j.1365-2567.1997.00348.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Deng G., Podack E. R. Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2189–2193. doi: 10.1073/pnas.90.6.2189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fluckiger A. C., Durand I., Banchereau J. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J Exp Med. 1994 Jan 1;179(1):91–99. doi: 10.1084/jem.179.1.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Georgescu L., Vakkalanka R. K., Elkon K. B., Crow M. K. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest. 1997 Nov 15;100(10):2622–2633. doi: 10.1172/JCI119806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hamzaoui A., Hamzaoui K., Kooli C., Chabbou A., Hentati F., Ayed K. High levels of bcl-2 protein in the T lymphocytes of patients with Behçet's disease. Clin Exp Rheumatol. 1996 Jan-Feb;14(1):106–107. [PubMed] [Google Scholar]
  9. Hamzaoui K., Ayed K. High affinity interleukin-2 receptors on peripheral blood lymphocytes are decreased during active Behçet's disease. Clin Exp Rheumatol. 1990 Jan-Feb;8(1):100–101. [PubMed] [Google Scholar]
  10. Hamzaoui K., Ayed K., Slim A., Hamza M., Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behçet's disease. Clin Exp Immunol. 1990 Jan;79(1):28–34. doi: 10.1111/j.1365-2249.1990.tb05122.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hamzaoui K., Hamzaoui A., Hentati F., Kahan A., Ayed K., Chabbou A., Ben Hamida M., Hamza M. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behçet's disease. J Rheumatol. 1994 Dec;21(12):2301–2306. [PubMed] [Google Scholar]
  12. Hamzaoui K., Hamzaoui A., Zakraoui L., Chabbou A. Levels of soluble Fas/APO-1 in patients with Behçet's disease. Mediators Inflamm. 1998;7(2):111–114. doi: 10.1080/09629359891261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hamzaoui K., Kahan A., Ayed K., Hamza M. Cytotoxic T cells against herpes simplex virus in Behçet's disease. Clin Exp Immunol. 1990 Sep;81(3):390–395. doi: 10.1111/j.1365-2249.1990.tb05344.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hang L., Theofilopoulos A. N., Dixon F. J. A spontaneous rheumatoid arthritis-like disease in MRL/l mice. J Exp Med. 1982 Jun 1;155(6):1690–1701. doi: 10.1084/jem.155.6.1690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hirohata S., Hashimoto T. Abnormal T cell responses to bacterial superantigens in Behçet's disease (BD). Clin Exp Immunol. 1998 May;112(2):317–324. doi: 10.1046/j.1365-2249.1998.00572.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ichikawa Y., Arimori K., Yoshida M., Horiki T., Hoshina Y., Morita K., Uchiyama M., Shimizu H., Moriuchi J., Takaya M. Abnormal expression of apoptosis-related antigens, Fas and bcl-2, on circulating T-lymphocyte subsets in primary Sjögren's syndrome. Clin Exp Rheumatol. 1995 May-Jun;13(3):307–313. [PubMed] [Google Scholar]
  17. Isomäki P., Söderström K. O., Punnonen J., Roivainen A., Luukkainen R., Merilahti-Palo R., Nikkari S., Lassila O., Toivanen P. Expression of bcl-2 in rheumatoid arthritis. Br J Rheumatol. 1996 Jul;35(7):611–619. doi: 10.1093/rheumatology/35.7.611. [DOI] [PubMed] [Google Scholar]
  18. Isomäki P., Söderström K. O., Punnonen J., Roivainen A., Luukkainen R., Merilahti-Palo R., Nikkari S., Lassila O., Toivanen P. Expression of bcl-2 in rheumatoid arthritis. Br J Rheumatol. 1996 Jul;35(7):611–619. doi: 10.1093/rheumatology/35.7.611. [DOI] [PubMed] [Google Scholar]
  19. Kahan A., Hamzaoui K., Ayed K. Abnormalities of T lymphocyte subsets in Behçet's disease demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies. J Rheumatol. 1992 May;19(5):742–746. [PubMed] [Google Scholar]
  20. Kaklamani V. G., Vaiopoulos G., Kaklamanis P. G. Behçet's Disease. Semin Arthritis Rheum. 1998 Feb;27(4):197–217. doi: 10.1016/s0049-0172(98)80001-2. [DOI] [PubMed] [Google Scholar]
  21. Kiraz S., Ertenli I., Benekli M., Calgüneri M. Parvovirus B19 infection in Behçet's disease. Clin Exp Rheumatol. 1996 Jan-Feb;14(1):71–73. [PubMed] [Google Scholar]
  22. Lorenz H. M., Grünke M., Hieronymus T., Herrmann M., Kühnel A., Manger B., Kalden J. R. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum. 1997 Feb;40(2):306–317. doi: 10.1002/art.1780400216. [DOI] [PubMed] [Google Scholar]
  23. Mizushima Y. Behçet's disease. Curr Opin Rheumatol. 1991 Feb;3(1):32–35. [PubMed] [Google Scholar]
  24. Nakamura S., Sugita M., Matoba H., Tanaka S., Isoda F., Ohno S. Insufficient expression of Fas antigen on helper T cells in Behçet's disease. Br J Ophthalmol. 1996 Feb;80(2):174–176. doi: 10.1136/bjo.80.2.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nakayama K., Nakayama K., Negishi I., Kuida K., Shinkai Y., Louie M. C., Fields L. E., Lucas P. J., Stewart V., Alt F. W. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science. 1993 Sep 17;261(5128):1584–1588. doi: 10.1126/science.8372353. [DOI] [PubMed] [Google Scholar]
  26. Nunez G., Seto M., Seremetis S., Ferrero D., Grignani F., Korsmeyer S. J., Dalla-Favera R. Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4589–4593. doi: 10.1073/pnas.86.12.4589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Raziuddin S., al-Dalaan A., Bahabri S., Siraj A. K., al-Sedairy S. Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol. 1998 Feb;25(2):329–333. [PubMed] [Google Scholar]
  28. Raziuddin S., al-Dalaan A., Bahabri S., Siraj A. K., al-Sedairy S. Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol. 1998 Feb;25(2):329–333. [PubMed] [Google Scholar]
  29. Schröter M., Lowin B., Borner C., Tschopp J. Regulation of Fas(Apo-1/CD95)- and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Eur J Immunol. 1995 Dec;25(12):3509–3513. doi: 10.1002/eji.1830251245. [DOI] [PubMed] [Google Scholar]
  30. Turan B., Gallati H., Erdi H., Gürler A., Michel B. A., Villiger P. M. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997 Jan;24(1):128–132. [PubMed] [Google Scholar]
  31. Veromaa T., Vainio O., Eerola E., Toivanen P. Monoclonal antibodies against chicken Bu-1a and Bu-1b alloantigens. Hybridoma. 1988 Feb;7(1):41–48. doi: 10.1089/hyb.1988.7.41. [DOI] [PubMed] [Google Scholar]
  32. Yazici H. The place of Behçet's syndrome among the autoimmune diseases. Int Rev Immunol. 1997;14(1):1–10. doi: 10.3109/08830189709116840. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES